HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing In Brief

This article was originally published in The Rose Sheet

Executive Summary

Croda: New Solaveil SpeXtra titanium-dioxide-based sunscreen dispersions are designed with "optimum particle size and shape," offering an option between micro-sized products on the market that have aesthetic appeal but provide inadequate UVA protection and products with larger particles that effectively guard against UVA radiation but show up white on skin, according to Croda's June 2 release. Solaveil SpeXtra boasts "balanced UVA and UVB efficacy with specialized control of the particle size distribution to moderate whitening on the skin," says the UK-based chemical suppliers' Edison, N.J. unit. The ingredient can be used alone to satisfy regulatory expectations in the EU where the "quantified minimum UVA protection" afforded by a sunscreen product is defined as one-third the SPF (1"The Rose Sheet" July 16, 2007). Solaveil SpeXtra is available in two versions - Solaveil XT-100 and Solaveil XT-300, both of which furnish photostable broad-spectrum UV protection, the former in a standard industry emollient and the latter in a naturally derived, Ecocert-certified carrier fluid "ideal for green formulations," Croda says
Advertisement

Related Content

Water, The Active Inactive? Mintel Examines Cosmetic H2O Innovations
Europe To Implement New Sunscreen Labeling, Efficacy Guides This Summer
Europe To Implement New Sunscreen Labeling, Efficacy Guides This Summer
Advertisement
UsernamePublicRestriction

Register

RS016979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel